You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

5389 Results
Guidelines and Advice
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Drug
Other Name(s): Imjudo®
Dec 1969
Document
Intro Text: Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam tempus urna nibh, et tempor nulla rhoncus vel. Maecenas sodales feugiat ex...
Document
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative, Palliative
Drugs Used:
azaCITIDine (Unfunded),
venetoclax (Unfunded),
gilteritinib (Unfunded)
Nov 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Sep 2025

Pages